|
Synonyms: compound 3 [US20220259184]
Compound class:
Synthetic organic
Comment: Fadeucravacitinib is the INN for a Janus kinase inhibitor with anti-inflammatory and immunosuppressant potential. The chemical structure was obtained from WHO INN Proposed List 135 (July 2026). The same chemical structure is claimed for TYK2 (the fourth member of the Janus kinase family) inhibitor activity in patent US2022259184A1 (Beijing Innocare Pharma) [1]. It is intended to target the TYK2 JH2 pseudokinase domain, so acts as an allosteric inhibitor. Beijing Innocare have declared an oral TYK2-JH2 inhibitor in their development pipeline, named ICP-488.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Chen X, Pang Y. (2022)
Heterocyclic compounds for inhibiting tyk2 activities. Patent number: US20220259184A1. Assignee: Beijing Innocare Pharma Tech Co Ltd. Priority date: 04/05/2022. Publication date: 18/08/2022. |